The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2013Characterization of LRRK2 Inhibitors for Advanced Drug-like Properties
Objective/Rationale:
Zenobia Therapeutics has identified a unique series of highly specific and potent LRRK2 inhibitors with central nervous system drug-like chemical properties using the... -
Rapid Response Innovation Awards, 2013Structure-based Design of Pharmacological Activators of Parkin
Objective/Rationale:
Mutations in the Parkin gene are responsible for a familial form of Parkinson’s disease (PD). The gene encodes a protein whose activity has been shown to protect... -
Research Grant, 2013LRRK2 Role on Auto-antibody Production by Human B Cells
Objective/Rationale:
B lymphocytes are cells of the immune system that have a dual function: they produce antibodies to fight disease-causing agents, and they participate in the... -
RRIA (Rapid Response Innovation Awards), 2013Role of GSK-3beta in Parkinson’s Disease
The protein GSK-3beta has not previously been linked to Parkinson’s disease (PD). Recently, we have studied pre-clinical models with high levels of GSK-3beta throughout the brain. At a younger age [up...
-
MJFF Research Grant, 2013Validation and Characterization of Exosomal Alpha-synuclein as a Diagnostic Marker for Parkinson’s Disease
Parkinson’s disease (PD) is characterized by aggregation of the intracellular alpha-synuclein protein and subsequent neurodegeneration. Recent findings suggest that extracellular alpha-synuclein forms...
-
Rapid Response Innovation Awards, 2012Polyglutamine Repeats and Parkinson Disease
Objective/Rationale:
Trinucleotide repeat expansion is a gene mutation where the codons (the groups of DNA components that correspond to amino acids) exceed the maximum of a certain gene...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.